Pancreatic cancer patients who cannot undergo curative surgery live as much as patients over 70 years old

Simple item page
dc.contributor.authorSerkan Y.
dc.contributor.authorPinar E.A.
dc.contributor.authorCengiz Y.
dc.contributor.authorAhmet O.
dc.contributor.authorFerhat E.
dc.contributor.authorGulcan B.
dc.date.accessioned2024-07-22T08:05:57Z
dc.date.available2024-07-22T08:05:57Z
dc.date.issued2021
dc.description.abstractPurpose: Patients over the age of 65 constitute approximately 54% of newly diagnosed cancers and approximately 70% of cancer-related deaths. These patients aged ≥65 years, who form the majority of clinical practice, are represented less in clinical studies than in real life. We designed this retrospective study to examine the treatment and response of patients to pancreatic cancer in patients over 70 years of age. Methods: Our study is a retrospective study that included patients from 5 centers in Turkey. Inclusion criteria were being over the age of 18 years, diagnosed with pancreatic cancer, and with ECOG performance score between 0-2. These patients were divided into two groups according to their age. The classification was made as patients over 70 years of age in the first group (geriatric group) and patients under 70 years of age (<70 age group) in the second group. Results: Overall survival of the <70 age group was statistically significantly longer (median 10 months vs 9.1 months p=0.027). When the patients who underwent only curative surgery were examined, the survival was statistically significant in favor of the <70 age group (median 20.96 months vs 14.5 months p=0.011). No statistically significant difference was found between the two groups in terms of the overall survival of patients with metastatic diagnosis (median 8.1 months vs 8.4 months p=0.182). Conclusion: The survival of patients with pancreatic cancer aged 70 and over was shorter than other age groups. While this difference was significant in patients who could undergo surgery at an early stage, it was not found in the metastatic patient group. Prospective larger-scale studies are needed to evaluate the treatment of geriatric patients better. © This work by JBUON is licensed under a Creative Commons Attribution 4.0 International License.
dc.identifier.issn11070625
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13310
dc.language.isoEnglish
dc.publisherZerbinis Publications
dc.subjectAge Factors
dc.subjectAged
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectPancreatic Neoplasms
dc.subjectRetrospective Studies
dc.subjectSurvival Rate
dc.subjectantineoplastic agent
dc.subjectcapecitabine
dc.subjectcapecitabine plus oxaliplatin
dc.subjectcisplatin
dc.subjectgemcitabine
dc.subjectaged
dc.subjectArticle
dc.subjectcancer combination chemotherapy
dc.subjectcancer surgery
dc.subjectcancer survival
dc.subjectclinical practice
dc.subjectcontrolled study
dc.subjectfemale
dc.subjectfollow up
dc.subjectgeriatric patient
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmetastasis
dc.subjectmulticenter study
dc.subjectoverall survival
dc.subjectpancreas cancer
dc.subjectretrospective study
dc.subjectTurkey (republic)
dc.subjectage
dc.subjectmortality
dc.subjectpancreas tumor
dc.subjectsurvival rate
dc.titlePancreatic cancer patients who cannot undergo curative surgery live as much as patients over 70 years old
dc.typeArticle

Files

Collections

Scopus Koleksiyonu